Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
Phase 1
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00458107
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This study is being conducted to evaluate the safety and tolerability of ascending multiple oral doses of SCA-136 adminstered to healthy Japanese and non-Japanese female subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 64
Inclusion Criteria
- Healthy Japanese women or non-Japanese of child bearing potential using nonhormonal contraceptives.
- Japanese female subjects are defined as being born in Japan but living outside of Japan for less than 5 years.
Exclusion Criteria
- Any significant disease.
- Positive urine drug screen, increased liver funtion tests, use of prescription drugs.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Adverse events, safety laboratories results, vital signs, and ECGs will be used to monitor subject safety.
- Secondary Outcome Measures
Name Time Method